Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Loathe to Disclose Probe Documents on Clinical Research Bill Leak
September 6, 2019
- In Fight against AMR, Japan Set to Forge Prefectural Networks to Push Proper Antibiotic Use
September 5, 2019
- Senior Bureaucrat Chided for Leaking Draft Clinical Research Bill
September 4, 2019
- Japan, Vietnam Regulators to Hold 1st Joint Symposium Next Month
September 4, 2019
- Japan Drug Production Up 2.8% to 6.9 Trillion Yen in 2018: MHLW
September 2, 2019
- MHLW’s Health Policy Bureau Requests Increased Budget for Core Hospitals, Centers for Pediatric and Rare Diseases
September 2, 2019
- MEXT Requests 103.4 Billion Yen to Fuel Healthcare R&D in FY2020
September 2, 2019
- METI Seeks 5.1 Billion Yen in FY2020 to Develop Technology Platforms for Cell and Gene Therapies
September 2, 2019
- Astellas’ “Post-Nesp” Renal Anemia Drug Now in Line for September Approval, 1st Forteo Biosimilar Too
August 30, 2019
- MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug
August 30, 2019
- Ultomiris Caught by CEA Rule despite Intractable Disease Indication: Chuikyo
August 29, 2019
- Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
August 29, 2019
- MHLW Seeks Record 32.6 Trillion Yen Budget for FY2020
August 28, 2019
- Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
- Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
August 28, 2019
- Public Knowledge-Based Filing OK’ed for Busulfex Use in Lymphoma HSCT
August 27, 2019
- Evenity under PMDA Risk Review
August 27, 2019
- Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
- Japan Eyes 1st Revision in 15 Years for Cancer Drug Development Guidelines to Deal with Rare Subtypes, Tumor-Agnostic Indications
August 27, 2019
- AbbVie’s Venetoclax Now in Line for September OK; Tecentriq’s Breast Cancer Use, 2nd Biosimilars and More
August 26, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…